Latest common stock for NDRAW: $120.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.
The latest common stock for NDRAW is $120 as of March 2026. That compares with $55 in the prior-year period — up 121.8% year over year. Investors often review this figure alongside ENDRA Life Sciences- Warrants (12/05/2022)'s historical trend and sector peers before judging valuation or financial health.
Over the past year, NDRAW's common stock moved from $55 to $120 — a 121.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in ENDRA Life Sciences- Warrants (12/05/2022)'s operating scale or balance-sheet position.
A common stock figure of $120 for NDRAW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.
After noting NDRAW's common stock ($120), review year-over-year change from $55, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack ENDRA Life Sciences- Warrants (12/05/2022)'s common stock against similar Technology names. You can also browse sector and industry screens on Stockcircle for a broader set of Technology companies and their key multiples and fundamentals.